文献速递遗传性与小管间质肾病慢性肾脏病

DNA甲基转移酶1促进常染色体显性多囊肾病囊肿生长与表观遗传年龄加速

DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age acceleration in autosomal dominant polycystic kidney disease.
PubMed 文献 · Kidney Int · 2024-05-21

在Pkd1突变小鼠及ADPKD患者肾脏中,DNMT1在囊性肾上皮细胞及组织中表达上调;敲除Dnmt1或用肼屈嗪靶向DNMT1可延缓囊肿生长并延长小鼠寿命。MBD-seq、ChIP-seq和RNA-seq鉴定出PTPRM和PTPN22为DNMT1新靶点,介导ERK、mTOR和STAT3通路磷酸化激活;全基因组亚硫酸氢盐测序显示ADPKD患者肾脏表观遗传时钟相关基因甲基化异常,支持表观遗传年龄加速。

要点

  • DNMT1在ADPKD囊肿上皮中上调,敲除或药物抑制可延缓囊肿生长。
  • PTPRM和PTPN22介导DNMT1对ERK、mTOR和STAT3通路的激活。
  • ADPKD患者肾脏表观遗传时钟相关基因甲基化异常,提示年龄加速。

核心结论

  • DNMT1在ADPKD中上调并促进囊肿生长,靶向DNMT1可延缓囊肿进展并延长模型小鼠寿命。
  • ADPKD患者肾脏存在表观遗传年龄加速,五个表观遗传时钟相关基因甲基化状态可能预测年龄加速并参与疾病进展。

研究设计与样本

  • 研究采用Pkd1突变小鼠模型与ADPKD患者肾脏组织,结合基因敲除、药物干预及多组学测序分析。

主要发现

  • DNMT1在囊性肾上皮细胞及组织中表达上调。
  • 敲除Dnmt1或用肼屈嗪靶向DNMT1可延缓Pkd1突变肾脏囊肿生长并延长Pkd1条件敲除小鼠寿命。
  • 鉴定出PTPRM和PTPN22为DNMT1新靶点,介导ERK、mTOR和STAT3通路的磷酸化激活。
  • ADPKD患者肾脏中表观遗传时钟相关基因甲基化异常,支持表观遗传年龄加速。
  • 鉴定出Hsd17b14、Itpkb、Mbnl1、Rassf5和Plk2五个表观遗传时钟相关基因。

临床怎么用

  • DNMT1及其下游PTPRM/PTPN22可能作为ADPKD治疗靶点,肼屈嗪作为安全去甲基化药物显示干预潜力。
  • 表观遗传时钟相关基因甲基化状态有望用于评估ADPKD疾病进展。

局限性

  • 研究主要基于Pkd1突变小鼠模型,DNMT1靶向治疗在ADPKD患者中的安全性和有效性尚未验证。
  • 表观遗传年龄加速与疾病进展的因果关系及五个基因甲基化状态的预测价值需进一步临床研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alteration of DNA methylation leads to diverse diseases, and the dynamic changes of DNA methylation (DNAm) on sets of CpG dinucleotides in mammalian genomes are termed "DNAm age" and "epigenetic clocks" that can predict chronological age. However, whether and how dysregulation of DNA methylation promotes cyst progression and epigenetic age acceleration in autosomal dominant polycystic kidney disease (ADPKD) remains elusive. Here, we show that DNA methyltransferase 1 (DNMT1) is upregulated in cystic kidney epithelial cells and tissues and that knockout of Dnmt1 and targeting DNMT1 with hydralazine, a safe demethylating agent, delays cyst growth in Pkd1 mutant kidneys and extends life span of Pkd1 conditional knockout mice. With methyl-CpG binding domain (MBD) protein-enriched genome sequencing (MBD-seq), DNMT1 chromatin immunoprecipitation (ChIP)-sequencing and RNA-sequencing analysis, we identified two novel DNMT1 targets, PTPRM and PTPN22 (members of the protein tyrosine phosphatase family). PTPRM and PTPN22 function as mediators of DNMT1 and the phosphorylation and activation of PKD-associated signaling pathways, including ERK, mTOR and STAT3. With whole-genome bisulfide sequencing in kidneys of patients with ADPKD versus normal individuals, we found that the methylation of epigenetic clock-associated genes was dysregulated, supporting that epigenetic age is accelerated in the kidneys of patients with ADPKD. Furthermore, five epigenetic clock-associated genes, including Hsd17b14, Itpkb, Mbnl1, Rassf5 and Plk2, were identified. Thus, the diverse biological roles of these five genes suggest that their methylation status may not only predict epigenetic age acceleration but also contribute to disease progression in ADPKD.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhou JX, Li LX, Zhang H, et al. DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age acceleration in autosomal dominant polycystic kidney disease. Kidney Int. 2024. PMID: 38782200. doi:10.1016/j.kint.2024.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。